Surgical approach to multifocal hepatocellular carcinoma with portal vein thrombosis and arterioportal shunt leading to portal hypertension and bleeding: a case report by Francesca Ratti et al.
WORLD JOURNAL OF 
SURGICAL ONCOLOGY 
Surgical approach to multifocal hepatocellular
carcinoma with portal vein thrombosis and
arterioportal shunt leading to portal hypertension
and bleeding: a case report
Ratti et al.
Ratti et al. World Journal of Surgical Oncology 2012, 10:34
http://www.wjso.com/content/10/1/34 (13 February 2012)
CASE REPORT Open Access
Surgical approach to multifocal hepatocellular
carcinoma with portal vein thrombosis and
arterioportal shunt leading to portal hypertension
and bleeding: a case report
Francesca Ratti*, Federica Cipriani, Michele Paganelli, Gianfranco Ferla and Luca AM Aldrighetti
Abstract
It is reported the case of a 69 years man who presented to the Emergency Room because of pain and abdominal
distension from ascites. After admission and paracentesis placement, he developed a digestive hemorrhage due to
oesophageal varices from portal ipertension secondary to the formation of a portal shunt concomitant with a
multifocal HepatoCellular Carcinoma (HCC) with portal vein thrombosis (PVT). The patient underwent endoscopic
varices ligation, twice transarterial embolization (TAE) of arterial branches feeding the shunt and subsequent left
hepatectomy. During the postoperative course he developed mild and transient signs of liver failure and was
discharged in postoperative day 16. He is alive and disease free 8 months after surgery.
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Background
The aggressiveness and invasiveness of Hepatocellular
Carcinoma (HCC) towards the main portal vein and
portal vein branches frequently causes the formation of
abnormal communications between vessels originating
from the hepatic artery and portal vein, creating an
arterioportal shunt (APS) [1]. Hemodynamic changes
resulting from the formation of this vascular abnormal-
ity tend to cause or worsen portal hypertension and
therefore to increase the incidence of major complica-
tions [2]. Transient complications of portal hypertension
lead to overestimation of patient’s class of risk, espe-
cially regarding postoperative liver failure: their recogni-
tion and treatment allows avoidance of inadvertent
exclusion from surgery [3], improving long term out-
come [4].
It is reported the case of a patient with multifocal
HCC complicated by the presence of APS and portal
vein thrombosis (PVT) diagnosed after an episode of
digestive hemorrhage from oesophageal varices.
Case presentation
Patient characteristics and treatment
A 69-years old male known for post alcoholic liver cir-
rhosis was admitted at the Division of Internal Medicine
through the Emergency Room because of abdominal
pain and distension, diarrhea and oliguria. Physical
examination revealed abdominal distension because of
severe ascites. Murphy and Blumberg signs were not
evocable. Laboratory data showed: white blood cells 5.3
10^9/L; haemoglobin 12.6 g/dL; platelets 98 10^9/L;
AST/ALT 66/90 U/L; PT ratio 1.10; aPTT ratio 0.92;
total bilirubin 0.75 mg/dL; Albumin 41.8 g/L; a-Feto-
protein 249.6 ng/mL; Creatinine 1.06 mg/dL. Child-
Pugh class was A7 (the patient took 2 points for ascites).
An abdominal ultrasonography revealed severe ascites,
multiple lesions in the left liver and absence of blood
flow in the left portal vein branch. A paracentesis was
then placed with drainage of 3 liters of clear ascites.
The day following admission hematemesis and melena
occurred due to bleeding from oesophageal varices: the
patient underwent upper gastrointestinal endoscopy
which revealed III grade blue varices, with red signs and
with blood clots in the gastric fundus. Endoscopic band
ligation of oesophageal varices was performed with
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success. Abdominal dynamic computed tomography
(CT) revealed low density confluent lesions in all phases
in the left lobe of the liver (Figure 1), an hyper-
enhanced portal vein during the arterial phase (Figure 2)
and a tumor thrombus in the left portal vein causing a
filling defect (Figure 3), ascites and splenomegaly. The
patient was diagnosed with HCC with severe intratu-
moral APS, which caused portal hypertension that lead
to oesophagogastric varices and hypersplenism. Since
the main cause of the portal hypertension was the APS,
transcatheter arterial embolization (TAE) was performed
twice. The preliminary angiography confirmed the pre-
sence of APS (Figure 4) and during the first TAE,
branches coming from left hepatic artery were embo-
lized (Figure 5). When a control CT scan was per-
formed, it revealed a persistent contrast enhancement of
the APS (Figure 6) that was refurnished from an arterial
vessel coming from the left gastric artery (Figure 7). A
second angiography and subsequent embolization mana-
ged to stop APS refilling. Therefore, after two days a left
hepatectomy was performed. Pathological examination
revealed a trabecular HCC with satellitosis, vascular
invasion and necrosis (pT3a, G3), a tumor thrombus in
the left branch of the portal vein, and active cirrhosis in
liver parenchyma. The postoperative course was compli-
cated by mild signs of liver failure with ascites (about
700 mL die) which resolved after treatment with diure-
tics and iv administration of albumin (Grade II accord-
ing to Dindo-Clavien classification of complications
following surgery) [5]. The patient was discharged in
postoperative day (POD) 16. The patient is alive and
disease free at 8 months after left hepatectomy.
Discussion
HCC is associated with the presence of intralesional
APS regarding the common portal vein in approximately
Figure 1 Confluent HCC lesions in the left lobe of liver.
Figure 2 Hyper-enhanced portal vein during the arterial phase.
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60% [6], or the main portal vein branches in 30% of
patients according to data reported by Okuda et al [7].
The presence of a high flow APS with hemodynami-
cally significant consequences, results in the creation or
worsening of portal hypertension, with potentially life
threatening complications such as oesophageal varices
rupture, refractory ascites, and liver encephalopaty [1-3].
The diagnosis of APS is reached through the execu-
tion of a contrast enhanced abdomen CT, revealing the
absence of atypical HCC radiologic features, a clear
enhancement of the portal vein axis contemporary to
the hepatic artery during the arterial phase of the exami-
nation and a lack of enhancement during the arterial
phase, since the blood flow to the lesion is reduced
because of the APS [8,9]. The diagnosis of multifocal
HCC with APS makes two issues arising: first, the treat-
ment of APS and, secondly, the treatment of HCC out
of Barcelona criteria [10].
Treatment options range from medical therapy alone
(Sorafenib), interventional radiology procedures (TAE to
treat the APS and/or transarterial chemoembolization
for the treatment of hepatic multifocal lesions) with or
without medical therapy, to radiological treatment of
the shunt (APS-TAE) and subsequent surgical liver
resection [11-14].
In this case report, in decision-making process two
sets of issues were taken into account: in the one hand,
the issue of APS in patients with HCC and, in the other
the treatment of hepatocellular malignancy out of Barce-
lona criteria.
Regarding the first point, the emergency treatment of
acute bleeding from esophageal varices may be made by
endoscopic ligation or sclerotherapy, and finally by TIPS
or surgical shunt if the control of portal hypertension is
not effective [15].
It is remarkable that in patients with APS the control
of portal hypertension is consequent to the treatment of
the shunt itself. Even if the rates of recanalization are
Figure 3 Tumor thrombus in the left portal vein.
Figure 4 Preliminary angiography confirming APS presence.
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high, as reported in the literature [16], in this case it was
decided to proceed with embolization of arterial blood
vessels feeding the shunt, with the dual aim of reducing
the risk of portal hypertension related complications
(also aggravated by portal vein thrombosis) and of gain-
ing better hemostatic control intraoperatively.
The need for a double session of embolization was
established by radiological finding of shunt persistence
due to arterial vessels originating from the left gastric
artery.
Control of portal hypertension resulted in ascites reso-
lution and re-classification of the patient in class A5
according to Child Pugh: if not, the patient would have
taken two points for ascites resulting in B7. This means
that transient complications of portal hypertension tend
to overestimate patient’s class of risk, especially regard-
ing postoperative liver failure. After shunt treatment
indeed, the patient was reported to the appropriate class
of Child and during the postoperative course, the
patient developed only mild and transient signs of liver
failure. Ishii et al. noted that in the presence of APS the
green indocyanin retention test proved to be unreliable
[17], since it overstates functional parenchymal impair-
ment [13].
Timing for surgery has to be decided in a case by case
analysis, considering the balance between complete
acute complication resolution and the risk of ischemic
or septic complications and APS recanalization.
A proper evaluation of the hepatic functional reserve,
prevents inappropriate exclusion of patients from the
only potentially curative treatment, because of risk
overestimation.
In the present case report, the patient presented with
multifocal disease, portal hypertension and malignant
PVT: the long term prognosis of these patients is quite
poor, so that Barcelona criteria do not indicate surgery
as the treatment of choice, since the 5-year survival rate
is less than 50% [10,18]. Despite of this, the most
Figure 5 APS embolization.
Figure 6 Persistent contrast enhancement of the portal vein.
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experienced surgical centers continue to perform liver
resection out of Barcelona indications [19], suggesting
that good long-term results are achievable, better than
those reported after non-curative treatments [10].
In particular, patients with PVT have a median survi-
val of 2.7 months without treatment [20]. On the con-
trary, following surgery, several authors report 3 years
survival rates ranging between 0 and 43% depending on
the series [21-24]. Furthermore, the presence of portal
hypertension is not a contraindication itself to invasive
approach or a predictor of outcome, as suggested by
Capussotti [25] and other authors [26,27].
Conclusion
In conclusion, the diagnostic and therapeutic strategy
proposed in this case is aimed to both the resolution
and prevention of acute complications of portal hyper-
tension and to offer a chance of long term survival
thanks to oncologic treatment. Transient complications
of portal hypertension have to be corrected before
deciding therapeutic strategy, as they tend to overesti-
mate patient’s class of risk and may induce inappropri-
ate exclusion of patients from surgery that is actually
able to improve long term survival.
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